首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1672945

腎母細胞瘤治療市場按類型、藥物類型、通路和地區分類

Nephroblastoma Treatment Market, By Type, By Drug Type, By Distribution Channel By Geography

出版日期: 2025年02月10日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球腎母細胞瘤治療市場規模估計為 18.7 億美元，預計到 2032 年將達到 26.3 億美元，2025 年至 2032 年的複合年成長率為 5.0%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	18.7億美元
效能資料	從 2020 年到 2024 年	預測期	2025 至 2032 年
預測期：2025-2032年複合年成長率：	5.00％	2032 年價值預測	26.3億美元

數字。 2025 年腎母細胞瘤治療市場佔有率（按地區分類）

腎母細胞瘤，也稱為威爾姆氏腫瘤，是兒童最常見的固態腫瘤之一。腎母細胞瘤始於腎臟，約佔所有兒童癌症的 6%。腎母細胞瘤的標準治療方法包括手術切除腫瘤，然後進行化療以殺死任何殘留的癌細胞。手術技術、化療方案和標靶治療的最新進展顯著提高了被診斷患有腎母細胞瘤的兒童的存活率。然而，抗藥性腫瘤的發展可能會阻礙市場成長。由於對提高治療效果和治療結果的創新產品的需求不斷增加，腎母細胞瘤治療市場可能會成長。

市場動態

腎母細胞瘤治療市場的成長主要受到全球兒童腎癌發生率上升的推動。根據聖猶達兒童研究醫院2022年發布的資料，腎母細胞瘤影響約每13,000名新生兒中的1名，佔所有兒童癌症的6-7％。診斷能力的提高和早期檢測意識的增強使得醫療保健提供者能夠在早期階段診斷出疾病，從而增加了對有效治療的需求。然而，手術和長期化療的高成本可能會阻礙市場的成長。正在進行的新型標靶治療和藥物組合研究為更有效地治療抗藥性腫瘤帶來了機會。

本研究的主要特點

本報告對全球腎母細胞瘤治療市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和複合年成長率。

它還揭示了各個領域的潛在商機並說明了該市場的引人注目的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球腎母細胞瘤治療市場的主要企業概況是根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行的。

研究涉及的主要企業包括默克公司、輝瑞公司、太陽製藥工業有限公司、Actiza Pharmaceutical Private Limited、Teva Pharmaceutical Industries Ltd.、Alvogen、Accord Healthcare Ireland Ltd.、Amneal Pharmaceuticals LLC.、卡迪拉製藥有限公司和 Xediton Pharmaceuticals。

本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

全球腎母細胞瘤治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員將透過用於分析全球腎母細胞瘤治療市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 1.87 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.00%	2032 Value Projection:	USD 2.63 Bn

Nephroblastoma, also known as Wilms' tumor, is one of the most common solid tumors occurring in children. It originates from nephrogenic rests in the kidneys and accounts for approximately 6% of all childhood cancers. The standard treatment approach for nephroblastoma involves surgical resection of the tumor, often followed by chemotherapy to eliminate any remaining cancer cells. Recent advancements in surgical techniques, chemotherapy regimens as well as targeted therapies have significantly improved the survival rates of children diagnosed with nephroblastoma. However, development of resistant tumors can hamper the market growth. Nephroblastoma treatment market can witness growth due to increasing demand for innovative products that can enhance treatment effectiveness and outcomes.

Market Dynamics

Nephroblastoma treatment market growth is primarily driven by rising incidence of kidney cancer in children worldwide. As per the data published by St. Jude Children's Research Hospital in 2022, nephroblastoma affects approximately 1 in 13,000 newborns and accounts for 6-7% of all childhood cancers. Improved diagnostic capabilities and increasing awareness regarding early detection enables healthcare providers to diagnose the condition at earlier stages, thus, boosting demand for effective therapeutics. However, high costs associated with surgery and prolonged courses of chemotherapy can hamper the market growth. Ongoing research into novel targeted therapies and drug combinations hold promising opportunities for treating resistant tumors more efficiently.

Key features of the study

This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global nephroblastoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Merck & Co., Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market

Market Segmentation

By Type Insights (Revenue, USD Bn, 2020 - 2032)
- Favorable histology
- Anaplastic histology
By Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Dactinomycin (Cosmegen)
- Doxorubicin (Adriamycin)
- Vincristine (Vincasar PFS, Oncovin)
- Cyclophosphamide (Cytoxan, Neosar)
- Etoposide (Toposar, VePesid)
- Irinotecan (Camptosar)
- Others
By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Merck & Co., Inc.
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Actiza Pharmaceutical Private Limited
- Teva Pharmaceutical Industries Ltd.
- Alvogen
- Accord Healthcare Ireland Ltd.
- Amneal Pharmaceuticals LLC.
- Cadila Pharmaceuticals Ltd.
- Xediton Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Nephroblastoma Treatment Market, By Type
- Nephroblastoma Treatment Market, By Drug Type
- Nephroblastoma Treatment Market, By Distribution Channel
- Nephroblastoma Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Epidemiology

4. Nephroblastoma Treatment Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Favorable histology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Anaplastic histology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Nephroblastoma Treatment Market, By Drug Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Dactinomycin (Cosmegen)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Doxorubicin (Adriamycin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Vincristine (Vincasar PFS, Oncovin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cyclophosphamide (Cytoxan, Neosar)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Etoposide (Toposar, VePesid)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Irinotecan (Camptosar)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Nephroblastoma Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Nephroblastoma Treatment Market, By Region, 2020 - 2032, (USD Bn)

Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Actiza Pharmaceutical Private Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alvogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Accord Healthcare Ireland Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amneal Pharmaceuticals LLC.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cadila Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Xediton Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies